The Trump-Xi meeting produced a one-year trade truce, but the two sides appear misaligned on what was agreed. Washington claims Beijing will effectively eliminate its rare-earths and critical material controls, but Beijing signals only limited easing through softer enforcement, rather than a formal rollback. Moreover, Trump has repeatedly shown his willingness to redraw the lines of national security, leaving Beijing space to negotiate further concessions.
Netherlands-based and Chinese-owned chip firm Nexperia recently became collateral damage in the US-China tech rivalry, and the Dutch government’s seizure of the company is a belated effort to regain control of a strategic technology asset. After repeated false dawns, it now seems that China is on the verge of peaking its coal consumption, thanks largely to its investments in renewables. And Chinese biotech firms are racing ahead in trialing innovative new cell and gene therapies for cancer.